ACADHIGH SIGNALFINANCIAL10-K

ACAD achieved explosive 243% revenue growth to $726M but operating income plummeted 55% despite the revenue surge, while cash reserves declined 44% to $178M.

The dramatic revenue growth suggests successful commercialization of trofinetide, but the counterintuitive collapse in operating income amid record sales indicates either massive one-time charges or unsustainable cost structure expansion. The simultaneous depletion of nearly half the cash reserves while generating strong revenue growth raises questions about working capital management and cash conversion efficiency.

Comparing 2026-02-26 vs 2025-02-27View on EDGAR →
FINANCIAL ANALYSIS

ACAD delivered exceptional top-line growth with revenue increasing 243% to $726M and gross profit surging 247% to $685M, demonstrating strong product commercialization. However, operating income collapsed 55% to $105M despite the revenue explosion, while cash reserves fell 44% to $178M and capital expenditures jumped 797% to $5M, suggesting significant investment in infrastructure. The overall picture shows a company successfully scaling revenue but struggling with cost control and cash management during rapid growth, creating both opportunity from commercial success and risk from operational execution challenges.

FINANCIAL STATEMENT CHANGES
Capital Expenditure
Cash Flow
+796.7%
$523K→$4.7M

Capital expenditure jumped 796.7% — major investment cycle underway; assess returns on deployment.

Gross Profit
P&L
+247.5%
$197.1M→$684.8M

Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.

Revenue
P&L
+243.1%
$211.7M→$726.4M

Strong top-line growth of 243.1% — accelerating demand or successful expansion into new markets.

Net Income
P&L
+72.7%
$226.5M→$391.0M

Net income grew 72.7% — bottom-line growth signals improving overall business health.

Stockholders Equity
Balance Sheet
+67.5%
$732.8M→$1.2B

Equity base grew 67.5% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Operating Income
P&L
-54.6%
$230.8M→$104.8M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

Cash & Equivalents
Balance Sheet
-44.4%
$319.6M→$177.7M

Cash declined 44.4% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Total Assets
Balance Sheet
+31.7%
$1.2B→$1.6B

Asset base grew 31.7% — expansion through organic growth, acquisitions, or capital deployment.

Operating Cash Flow
Cash Flow
-30.4%
$157.7M→$109.8M

Operating cash flow fell 30.4% — earnings quality concerns; investigate working capital changes and non-cash items.

Current Liabilities
Balance Sheet
-29.8%
$394.9M→$277.1M

Current liabilities reduced — improved short-term financial position and working capital health.

LANGUAGE CHANGES
NEW — 2026-02-26
PRIOR — 2025-02-27
ADDED
As of February 18, 2026, 170,494,613 shares of the registrant s common stock, $0.0001 par value, were outstanding.
The regulatory approval processes in the EU and outside North America are lengthy, time consuming and inherently unpredictable, and, if we do not obtain regulatory approval of trofinetide outside North America, we will not be able to market trofinetide outside North America, which will limit our trofinetide commercial revenues.
International trade policies, including tariffs, sanctions and trade barriers may adversely affect our business, financial condition, results of operations and prospects.
We have incurred, and expect to continue to incur, significant costs as a result of laws, regulations and standards relating to various aspects of our business, including corporate governance, work force initiatives and other matters, and failure to comply with such laws, regulations and standards could adversely affect our business.
Company Overview We are a biopharmaceutical company focused on turning scientific promise into meaningful innovation that makes the difference for underserved neurological and rare disease communities around the world.
+7 more — sign up free →
REMOVED
As of February 18, 2025, 166,788,517 shares of the registrant s common stock, $0.0001 par value, were outstanding.
If we do not obtain regulatory approval of trofinetide outside North America, we will not be able to market trofinetide outside North America, which will limit our commercial revenues.
We have a history of net losses and we may not be able to predict the extent of future losses.
We have incurred, and expect to continue to incur, significant costs as a result of laws and regulations relating to corporate governance and other matters.
Company Overview We are a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →